Earnings Feed
Start Free
Home/Filings/4/0000899243-17-024268
4//SEC Filing

Blobel Friedhelm 4

Accession 0000899243-17-024268

CIK 0000880771other
View on SEC.govCompany Profile

Filed

Oct 15, 8:00 PM ET

Accepted

Oct 16, 5:17 PM ET

Size

42.0 KB

Accession

0000899243-17-024268

Insider Transaction Report

Form 4
Period: 2017-10-13
SCICLONE PHARMACEUTICALS INCSCLN
Blobel Friedhelm
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2017-10-13+95,000→ 237,299 total
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-13−10,000→ 0 total
    → Common Stock (10,000 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$2.06/sh−11,243$23,161→ 0 total
    Exercise: $9.12Exp: 2026-03-15→ Common Stock (11,243 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$1.53/sh−10,843$16,590→ 0 total
    Exercise: $9.65Exp: 2027-03-08→ Common Stock (10,843 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-13−20,000→ 0 total
    → Common Stock (20,000 underlying)
  • Award

    Common Stock

    2017-10-13+150,000→ 387,299 total
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$1.53/sh−129,157$197,610→ 0 total
    Exercise: $9.65Exp: 2027-03-08→ Common Stock (129,157 underlying)
  • Disposition to Issuer

    Common Stock

    2017-10-13$11.18/sh−387,299$4,330,003→ 0 total
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$6.05/sh−142,610$862,791→ 0 total
    Exercise: $5.13Exp: 2021-05-12→ Common Stock (142,610 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$4.96/sh−200,000$992,000→ 0 total
    Exercise: $6.22Exp: 2022-03-15→ Common Stock (200,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$6.66/sh−200,000$1,332,000→ 0 total
    Exercise: $4.52Exp: 2024-03-14→ Common Stock (200,000 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-13−50,000→ 0 total
    → Common Stock (50,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.06/sh−128,757$265,239→ 0 total
    Exercise: $9.12Exp: 2026-03-15→ Common Stock (128,757 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-10-13−15,000→ 0 total
    → Common Stock (15,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$6.65/sh−200,000$1,330,000→ 0 total
    Exercise: $4.53Exp: 2023-04-04→ Common Stock (200,000 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2017-10-13$2.35/sh−42,725$100,404→ 0 total
    Exercise: $8.83Exp: 2025-03-16→ Common Stock (42,725 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2017-10-13$2.35/sh−97,275$228,596→ 0 total
    Exercise: $8.83Exp: 2025-03-16→ Common Stock (97,275 underlying)
Footnotes (14)
  • [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
  • [F10]Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F11]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
  • [F12]Granted under Issuer's 2015 Equity Incentive Plan.
  • [F13]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F14]Under its terms the option became exercisable in installments with 25% to vest on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
  • [F2]Includes 216 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on October 6, 2017 and 746 shares of SCLN common stock acquired under Issuer's 2016 Employee Stock Purchase Plan on August 31, 2017.
  • [F3]Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities.
  • [F4]Granted under Issuer's 2005 Equity Incentive Plan.
  • [F5]Under its terms the option became exercisable in installments with 25% vesting on April 5, 2012 and 2.0833% vesting each month thereafter until it became vested in full on April 5, 2015.
  • [F6]The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
  • [F7]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2013 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2016.
  • [F8]Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017.
  • [F9]Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.

Documents

1 file

Issuer

SCICLONE PHARMACEUTICALS INC

CIK 0000880771

→
Entity typeother

Related Parties

1
  • filerCIK 0001363213

Filing Metadata

Form type
4
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:17 PM ET
Size
42.0 KB
View on SEC.gov